BMEA Fundamental Analysis - BIOMEA FUSION INC

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to BMEA. BMEA was compared to 558 industry peers in the Biotechnology industry. While BMEA seems to be doing ok healthwise, there are quite some concerns on its profitability. BMEA does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year BMEA has reported negative net income.

In the past year BMEA has reported a negative cash flow from operations.

In the past 5 years BMEA always reported negative net income.

BMEA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

BMEA has a worse Return On Assets (-233.63%) than 91.58% of its industry peers.

With a Return On Equity value of -447.60%, BMEA is not doing good in the industry: 77.06% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-233.63%
ROE	-447.6%
ROIC	N/A

ROA(3y)-98.37%

ROA(5y)-65.2%

ROE(3y)-137.7%

ROE(5y)-89.02%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BMEA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for BMEA has been increased compared to 1 year ago.

BMEA has more shares outstanding than it did 5 years ago.

BMEA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

BMEA has an Altman-Z score of -16.77. This is a bad value and indicates that BMEA is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -16.77, BMEA is doing worse than 82.08% of the companies in the same industry.

BMEA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-16.77

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 2.25 indicates that BMEA has no problem at all paying its short term obligations.

BMEA has a Current ratio of 2.25. This is in the lower half of the industry: BMEA underperforms 72.58% of its industry peers.

BMEA has a Quick Ratio of 2.25. This indicates that BMEA is financially healthy and has no problem in meeting its short term obligations.

BMEA's Quick ratio of 2.25 is on the low side compared to the rest of the industry. BMEA is outperformed by 70.79% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.25
Quick Ratio	2.25

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 0.56% over the past year.

EPS 1Y (TTM)0.56%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%26.61%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BMEA will show a small growth in Earnings Per Share. The EPS will grow by 6.49% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y42.05%

EPS Next 2Y22.36%

EPS Next 3Y16.89%

EPS Next 5Y6.49%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BMEA. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BMEA. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

BMEA's earnings are expected to grow with 16.89% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y22.36%

EPS Next 3Y16.89%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for BMEA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BIOMEA FUSION INC

NASDAQ:BMEA (5/30/2025, 8:00:01 PM)

Premarket: 1.44 0 (0%)

1.44

-0.05 (-3.36%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-05 2025-05-05/amc

Earnings (Next)07-31 2025-07-31/amc

Inst Owners63.53%

Inst Owner Change-6.92%

Ins Owners15.36%

Ins Owner Change0%

Market Cap54.10M

Analysts81.43

Price Target25.5 (1670.83%)

Short Float %31.13%

Short Ratio13.57

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-7.21%

Min EPS beat(2)-28.2%

Max EPS beat(2)13.79%

EPS beat(4)3

Avg EPS beat(4)-0.66%

Min EPS beat(4)-28.2%

Max EPS beat(4)13.79%

EPS beat(8)5

Avg EPS beat(8)0.42%

EPS beat(12)6

Avg EPS beat(12)-2.71%

EPS beat(16)6

Avg EPS beat(16)-7.34%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-17.36%

EPS NQ rev (1m)-8.01%

EPS NQ rev (3m)42.18%

EPS NY rev (1m)4.58%

EPS NY rev (3m)35.04%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)-100%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	1.88
P/tB	1.88
EV/EBITDA	N/A

EPS(TTM)-3.55

EYN/A

EPS(NY)-1.93

Fwd EYN/A

FCF(TTM)-3.03

FCFYN/A

OCF(TTM)-3.02

OCFYN/A

SpS0

BVpS0.76

TBVpS0.76

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-233.63%
ROE	-447.6%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-98.37%

ROA(5y)-65.2%

ROE(3y)-137.7%

ROE(5y)-89.02%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	18.21%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.25
Quick Ratio	2.25
Altman-Z	-16.77

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)130.81%

Cap/Depr(5y)432.09%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)0.56%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%26.61%

EPS Next Y42.05%

EPS Next 2Y22.36%

EPS Next 3Y16.89%

EPS Next 5Y6.49%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y3.24%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-0.65%

EBIT Next 3Y3.1%

EBIT Next 5Y-5.65%

FCF growth 1Y-41.77%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-48.46%

OCF growth 3YN/A

OCF growth 5YN/A

BIOMEA FUSION INC (BMEA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens